Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer

Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer

The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI.

The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.

The study will consist of creation a tumor tissue bank, all sampling will be stored in the biological resources center of Ambroise Paré hospital.

Inclusion Criteria:

• Diagnosed NSCLC or SCLC;
• Patient treated priorly by ICI and progressed under ICI;
• Have provided written informed consent for the study;
• Be >/= 18 years of age on day of signing informed consent.

Exclusion Criteria:

• Patient under guardianship or curatorship;
• Unable to provide written informed consent for the study;
• Technical impossibility to carry out tissular rebiopsy under local anesthesia.